Related Experiment Video

Updated: Jul 4, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K

Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer

Gerhard Hamilton1, Sandra Stickler1, Barbara Rath1

  • 1Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.

Current Cancer Drug Targets
|January 26, 2024
PubMed

Insights

Novel PROTACs targeting BRD4 show promise for treating small cell lung cancer (SCLC). ARV-825 demonstrates significant anti-cancer effects, potentially improving chemotherapy outcomes for this aggressive neuroendocrine carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Small cell lung cancer (SCLC) has a poor prognosis and resistance to current therapies.
  • Tumor suppressors TP53 and RB1 are often inactivated, while MYC oncogenes are overexpressed in SCLC.
  • Targeting MYC directly is challenging due to its structure and limited inhibitor efficacy.

Purpose of the Study:

  • To explore novel therapeutic strategies for SCLC by targeting MYC indirectly.
  • To investigate the efficacy of BET inhibitors, specifically PROTACs, against SCLC.
  • To evaluate the anti-proliferative and cytotoxic effects of ARV-825 on SCLC cell lines.

Main Methods:

  • Discussion of novel BET-directed Proteolysis Targeting Chimeras (PROTACs).
  • Evaluation of ARV-825, a specific BRD4 inhibitor.
  • Assessment of antiproliferative and cytotoxic activity in SCLC cell lines.

Main Results:

  • Novel BET-directed PROTACs exhibit high antiproliferative activity in SCLC.
  • ARV-825 shows superior cytotoxic effects on SCLC cell lines.
  • BRD4 inhibition reduces the expression of the oncogenic driver MYC.

Conclusions:

  • BET inhibitors, particularly PROTACs like ARV-825, represent a promising therapeutic avenue for SCLC.
  • ARV-825 may serve as a valuable addition to SCLC combination chemotherapy regimens.
  • Targeting BRD4 offers an indirect strategy to suppress MYC-driven tumor growth in SCLC.
Keywords:
BET inhibitorsDNA damage response (DDR).MYC paralogsPROTACSmall cell lung cancerbromodomain proteins

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K